APP Pharma signs commercialization, manufacturing pact with Teva
As per the terms of the agreement, Teva Pharma has licensed APP Pharma to market Gemcitabine HCI for Injection in 200mg and 1g single dose vials during the
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.